Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Not yet recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 425Neoplasms 284Carcinoma, Non-Small-Cell Lung 274Colorectal Neoplasms 236Prostatic Neoplasms 173Lung Neoplasms 171Carcinoma, Hepatocellular 157Stomach Neoplasms 126Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 118Multiple Myeloma 106Recurrence 100Uterine Cervical Neoplasms 97Squamous Cell Carcinoma of Head and Neck 89Neoplasm Metastasis 88Rectal Neoplasms 87Ovarian Neoplasms 81Triple Negative Breast Neoplasms 78Small Cell Lung Carcinoma 72Head and Neck Neoplasms 70Brain Neoplasms 70Glioblastoma 65Esophageal Neoplasms 65Endometrial Neoplasms 59Colonic Neoplasms 59Melanoma 56Hematologic Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Motor Activity 48Glioma 48

Interventions

sparsentan 1anlotinib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Proteinuria × Clear all
NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1 Not yet recruiting
20 enrolled

Neoplasms, Proteinuria

NCT07358520 2026-01-22

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Fudan University

Phase 4 Not yet recruiting
40 enrolled

Proteinuria

NCT07355361 2026-01-21

N093

Fudan University

Phase 2 Not yet recruiting
120 enrolled

Proteinuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡